Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 19, 2026.

Metallic ions as therapeutic agents in tissue engineering scaffolds: an overview of their biological applications and strategies for new developments

Viviana Mouriño, Juan Pablo Cattalini, Aldo R. Boccaccini

Journal of The Royal Society Interface · 2011 · Review

doi:10.1098/rsif.2011.0611

Abstract

This article provides an overview on the application of metallic ions in the fields of regenerative medicine and tissue engineering, focusing on their therapeutic applications and the need to design strategies for controlling the release of loaded ions from biomaterial scaffolds. A detailed summary of relevant metallic ions with potential use in tissue engineering approaches is presented. Remaining challenges in the field and directions for future research efforts with focus on the key variables needed to be taken into account when considering the controlled release of metallic ions in tissue engineering therapeutics are also highlighted.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

A common tissue engineering approach involves the development of novel biomaterials to produce three-dimensional porous scaffolds, that encourage cell infiltration and proliferation for tissue regeneration. Several debilitating and deadly conditions such as osteoporosis, osteoarthritis, retinopathy, burns, myocardial infarction as well as tendon and ligament defects, among others have the potential to be treated by tissue engineering strategies. Scaffolds made from biodegradable polymers, ceramics or their composites are popular choices for tissue engineering applications and there are increasing investigations focusing on loading engineered scaffolds with therapeutic drugs, generating a dual function for the matrices: scaffolds for the growth of new tissue and carriers for controlled in situ drug delivery. In addition, there is growing interest in developing matrices with the capacity to induce specific interactions within cells in order to unlock the innate path for self-repair. Further, it is worthwhile noting the current expansion of the field of therapeutic tissue engineering (TTE), which considers the enhancement of the functionality of scaffolds by incorporating a drug delivery function with therapeutic effectiveness. In this context, in order to design and develop TTE scaffolds, several variables have to be taken into account. From a tissue engineering perspective, selection of suitable processing methods that provide the best mechanical and structural properties to the final porous scaffold is of highest relevance. From a pharmaceutical perspective, the scaffold fabrication method must be compatible with drug stability and sustained drug release; conditions such as high temperature, use of some organic solvents, pressure and free radicals that may lead to drug decomposition will restrict the selection of fabrication processes. There are several otherwise very convenient fabrication techniques for tissue engineering scaffolds, involving however, processes that are incompatible with the incorporation and stability of organic drugs. It is therefore attractive to explore the use of metallic ions as therapeutic agents (MITAs) within the scope of TTE. A wide range of MITA, the majority of them being essential cofactors of enzymes, can be considered in this regard, including cobalt, copper, gallium, iron, manganese, silver, strontium, vanadium and zinc, and will be discussed further in this article. The use of MITA does not pose the risk of decomposition or instability, which is intrinsic to organic molecules. Further, the unique properties of MITA with therapeutic significance (e.g. hydrolytic and redox activity, Lewis acidity, electrophilicity, valency, geometry, magnetic effect, spectroscopy, radiochemical properties) indicate the ability of these ions to interact with other ions that can alter cellular functions, cell metabolism or biological functions, by binding to macromolecules such as enzymes and nucleic acids, and/or activating ion channels or secondary signalling. These actions of MITA may provide effects that are different from those that can be achieved through other chemical, biochemical or genetic manipulations. In addition, an MITA approach is usually economic and stable under typical processing conditions for biomaterial scaffold production, which may involve the use of organic solvents, high temperatures, pressure and free radicals. Nevertheless, the potential toxicity of metallic ions when delivered locally has to be taken into account. From this perspective, the purpose of this review is to provide an overview of the advances in the expanding field of application of metallic ions in regenerative medicine and tissue engineering, focusing on their therapeutic applications. Particular emphasis is given to bone tissue engineering (TE), as this particular TE area seems to be the more developed regarding the use of MITA (also named bioinorganics). This article is not encyclopaedic; rather, selected examples have been chosen to illustrate and summarize the progress in the research field. In addition, some works that detail the use of MITA to regulate specific metabolic processes are included despite not yet being used in tissue engineering, but with the potential to be considered in future TE strategies. The article is organized in the following manner: §2 discusses the general local release of metallic ions and their interaction with metabolic processes, §3 focuses on the key variables needed to be taken into account when considering the inclusion of MITA in controlled drug delivery systems in general and in scaffolds for tissue engineering in particular. Finally, remaining challenges in the field and directions for future research efforts are highlighted in §4.

Localized release of metallic ions

In the body, various metallic ions act as cofactors of enzymes and stimulate a chain of reactions associated with cell signalling pathways towards tissue equilibrium. These properties, far from specific, are reflected in the very wide range of pathological conditions in which metallic ions are involved. Interactions with metallic ions play important roles in a variety of diseases and metabolic disorders such as cancer, central nervous system disorders, infectious diseases, perturbation of gastrointestinal activity and endocrine disorders; studies based on the effects of metallic ions in a wide range of pathologies are reviewed in the literature. Thus, the efficiency and selectivity of the therapeutic effect of metallic ions can be improved by controlling the precise level and/or location of them in the body. In addition, the ionic states of certain metallic ions are unstable, and they may have toxic effects when directly ingested. To overcome these disadvantages, extensive research has been conducted to develop matrices to control the local release of metallic ions. Current metallic-ion-based drugs are prone to lead to significant systemic toxicity; thus, the design of matrices for the local delivery of relatively high concentrations of metallic-ion-based drugs to target tissues with reduced systemic adverse effects is of high interest. The degree of metallic ion loading into matrices for local delivery and the controlled and sustained release of the loaded ions are undoubtedly important to ultimately optimize metal ion delivery for therapeutic use. In addition, it is imperative to control the release rate of loaded ions. Nevertheless, ascertaining the appropriate degree of metallic ion loading and the appropriate amount released in a determined period is difficult because therapeutic levels of most MITA are unknown. A strategy very often used to load metallic ions into matrices is to bind them to a suitable substrate (zeolites, hydroxyapatite, bioactive glass, silica, carbon fibres) so that the stability of ionic states is improved and the ions can be released over a long period of time with potential applications in many fields. Despite the efforts made in this respect, the achievements in controlling and sustaining the release of loaded therapeutic metal ions—in terms of obtaining constant therapeutic amount release of the ion over a period of time—have been very limited. Amorphous peroxititanates (APT) might also be used to bind a variety of metal compounds with high-affinity forming complexes to control the delivery of metal-based drugs to the target tissue avoiding systemic toxicity, or to capture metal ions from body tissues. Wataha et al. demonstrated that metal–APT complexes facilitate metal ion delivery (such as gold and platinum) to monocytes as well as fibroblasts. Despite the improvements made in controlling ion release from a variety of biomaterials, potential accumulation and toxicity require further research. In healthy systems, free metallic ion concentrations are maintained at very low levels, and the normal metal metabolism delivers them in a selective manner to their sites of action, while maintaining rigid control over their reactivity. However, anomalous metallic ion metabolism can contribute to pathological states such as haemochromatosis, Wilson disease and Menkes disease. Moreover, as mentioned above, the singular properties of metallic ions, such as Lewis acidity, hydrolytic and redox activity, electrophilicity and valency, can alter cellular activities supporting the cell metabolism or, in the worse case scenario, inducing toxic effects. For example, minimal shortages of certain metallic ions are involved in the pathogenesis of various chronic diseases such as diabetes mellitus, rheumatoid arthritis, coronary heart disease, epilepsy, nephropathy and a variety of bone-related pathologies. By contrast, the uncontrolled release of metal ions may produce adverse effects such as the case of corrosion of metal implants, which causes the release of significant amounts of metal ions into the tissues in close contact with the implant and the systemic circulation, often resulting in complications such as inflammatory and immune reactions. The actions of MITA loaded within matrices for local release in general, and within scaffolds for tissue engineering in particular, may be different from those that can be achieved through other chemical, biochemical or genetic interactions. The local actions of MITA within the environment in which they are released are presumed to differ in general from the actions of non-metallic agents, offering singular therapeutic opportunities. On the other hand, it is important to gain control over the potential toxicity of MITA, and the appropriate therapeutic concentrations for local release must be defined. In this context and considering the growing interest in the local release of metallic ions for therapeutic purposes, the following issues must be taken into consideration: (i) reactions of metallic ions with cellular constituents (e.g. proteins, nucleic acids—DNA and RNA—lipids, carbohydrates, redox substrates, signalling molecules); (ii) reactions of metallic ions in the local cellular environment; (iii) incorporation of metallic ions into cells and delivery to specific organelles and cellular structures; and (iv) interactions of metallic ions with specific receptors and enzymes and their involvement in metabolic pathways to alter cell functions.

Therapeutic ions in tissue engineering

The interest in the application of MITA in the field of regenerative medicine and TE scaffold development is growing owing to the fact that MITA may offer therapeutic opportunities coupled with high flexibility to be incorporated in engineered biomaterial scaffolds by a broad range of processing methods. Moreover, MITA have lower cost, higher stability and potentially greater safety than recombinant proteins or genetic engineering approaches. Table 1 summarizes the most common processes reported to produce scaffolds for tissue engineering with the potential to be used for the incorporation of MITA in scaffolds. Processing techniques such as rapid prototyping, electrospinning, thermally induced phase separation and solid free form fabrication are attractive because they enable fabrication of engineered three-dimensional, porous structures of high uniformity and reproducibility. Additionally, organic/inorganic composite scaffolds, particularly for bone tissue engineering applications, made of bioceramics or bioactive glasses and biodegradable polymers, often include metallic ions as part of the bioceramic or bioactive glass structural composition. These inorganic materials enable metal ion release during their degradation in vitro or in vivo. For example, when bioactive glass (e.g. 45S5 Bioglass) is used in scaffolds for bone tissue engineering and introduced to fill a bone defect, critical concentrations of soluble Si, Ca, P and Na ions are released, with the capability to produce both intracellular and extracellular effects at the interface between the glass and the cellular environment. These ions are known to stimulate various processes; for example, several investigations have demonstrated that released ions from bioactive glasses are able to induce gene expression with known roles in processes related to bone metabolism by signal transduction, thereby enhancing cell differentiation and osteogenesis. The ionic dissolution products of bioactive glasses can also promote angiogenesis. It is, therefore, vital that the kinetics of ion release from any scaffold (or implant) made from bioceramics can be tailored and controlled. A comprehensive review about the biological response to ionic dissolution products from glass–ceramics and bioactive glasses in the context of bone tissue engineering has been recently published. Nevertheless, it is important to highlight that few studies are focused on developing ideal matrices for the control and sustained release of loaded ions within specific therapeutic levels, over a previously defined period of time. Several attempts to intentionally load therapeutic metal ions rely on ion substitution in ceramic systems, limiting the possibility to control and sustain the release of a specific therapeutic dose over a period of time. In this sense, the application of inorganic ions in the field of bone regeneration, with special emphasis on the lack of a controlled, sustained and localized release of both structural and non-structural ions from bioceramics, is discussed in a recent report of Habibovic & Barralet. Novel strategies are based on biodegradable metals, such as magnesium alloys and iron, which are dissolved in vivo when no longer needed. In this regard, research activities are underway to make biodegradable metals practical for tissue engineering. There are also new techniques to produce degradable metallic implants, innovative coating technologies to yield special surface functionalities, new biodegradable materials and methods to develop nano-devices for monitoring implants and sensing functions. In addition, the use of metallic ions as cross-linkers of polymers in the formation of hydrogels and as network formers or modifiers of bioactive glasses (silicate or phosphate systems) in the elaboration of bioactive scaffolds are being increasingly investigated. Figure 1 provides a summary of the most common specific targets of relevant metallic ions reviewed in the present work in their role as therapeutic agents. Table 2 summarizes relevant functions and biological effects of metallic ions with promising applications in tissue engineering. As indicated above, one of the obvious negative effects of the localized release of ions could be potential ion accumulation and toxicity. It is, therefore, vital that the kinetic of ion release from any scaffold is tailored. Several investigations have shown how the incorporation of specific metallic ions in different matrices could affect (usually improve) the physiology and metabolism of cells close to the release area; a summary of previous investigations is presented in table 3. The list is intended to be illustrative, not exhaustive. The number of specific investigations on effects of MITA intentionally added to scaffolds for therapeutic purposes, aimed at engineering a wide range of tissues, is continuously growing. Particularly, in the case of bone TE, there is increasing interest in the role of certain metallic ions (e.g. copper, strontium and zinc) in bone pathologic states because many of them are cofactors in metabolic processes involving bone, articular tissues and immune system functions. Further, the loading of MITA within scaffolds lacks the risk of drug decomposition or instability depending on the employed processes of fabrication, as explained above. Moreover, bacterial adhesion to biomaterials that causes biomaterial-centred infection and poor tissue integration are problems that could limit the viability of the scaffold, especially when it is designed to be applied in vivo (as opposed to applications in bioreactors, for example). As mentioned above, there is growing interest in exploring the possibility of using the device itself to deliver therapeutic drugs to prevent possible bacterial colonization of the device following implant surgery and/or pro-angiogenic agents to secure vascularization. In this context, bacteriostatic effect and pro-angiogenic potential seem to be the most common aims of the incorporation of metallic ions within scaffolds to date and the most common ions studied in this regard are copper, silver, strontium and zinc (table 3).

Concluding remarks and future steps

Metallic ions are of interest in the fields of regenerative medicine and tissue engineering owing to the possibility of exploiting their unique advantages for therapeutic applications: reduced cost, increased stability and, in terms of safety, potentially lesser risk than techniques of recombinant proteins or genetic engineering. Several biomaterial-based strategies are being designed for the controlled-localized delivery of metallic ions and the field is continuously expanding. However, many challenges remain. First, there is a need to acquire a deep understanding of the roles of specific metals in cellular regulation and cell–cell signalling in both healthy and diseased tissue when they are released locally from scaffolds, implants or other releasing devices. Second, more in vivo evidence confirming that metallic ions can be released locally from scaffolds without systemic toxicity and carcinogenic effects is bound to follow. In addition, broader knowledge about mechanisms linking univocally the improved biological performance provided by TE scaffolds to the effect of metallic ions release is also needed. Much of the work is expected to involve collaborations, including biologists, material scientists, pharmaceutical technologists, tissue engineers and biomedical researchers. A great deal of further work is necessary but current investigations suggest that such work may be fruitful towards more effective tissue engineering strategies with improved MITA-releasing biomaterials. The final objective of this review has been thus to encourage research that bridges the areas at the interface between materials chemistry and medicine for developing new tissue engineering therapeutic strategies based on controlled metal ion release.

References 247

  1. 1.

    Langer R. Vacanti J. P. 1993 Tissue engineering. Science 260, 920–926. ()

    Not in our library10.1126/science.8493529

  2. 2.

    Cima L. G. Vacanti J. P. Vacanti C. Ingber D. Mooney D. Langer R. 1991 Tissue engineering by cell transplantation using degradable polymer substrates. J. Biomech. Eng. 113, 143–151. ()

    Not in our library10.1115/1.2891228

  3. 3.

    Hutmacher D. 2001 Scaffold design and fabrication technologies for engineering tissues: state of the art and future perspectives. J. Biomater. Sci. Polym. 12, 107–124. ()

    Not in our library10.1163/156856201744489

  4. 4.

    Sokolsky-Papkov M. Agashi K. Olaye A. Shakesheff K. Domb A. J. 2007 Polymer carriers for drug delivery in tissue engineering. Adv. Drug Deliv. Rev. 50, 187–206. ()

    Not in our library10.1016/j.addr.2007.04.001

  5. 5.

    Habraken W. Wolke J. G. C. Jansen J. A. 2007 Ceramic composites as matrices and scaffolds for drug delivery in tissue engineering. Adv. Drug Deliv. Rev. 59, 234–248. ()

    Not in our library10.1016/j.addr.2007.03.011

  6. 6.

    Tessmar J. K. Göpferich A. M. 2007 Matrices and scaffolds for protein delivery in tissue engineering. Adv. Drug Deliv. Rev. 59, 274–291. ()

    Not in our library10.1016/j.addr.2007.03.020

  7. 7.

    De Laporte L. D. Shea L. 2007 Matrices and scaffolds for DNA delivery in tissue engineering. Adv. Drug Deliv. Rev. 59, 292–307. ()

    Not in our library10.1016/j.addr.2007.03.017

  8. 8.

    Moioli E. K. Clark P. A. Xin X. Lal S. Mao J. J. 2007 Matrices and scaffolds for drug delivery in dental, oral and craniofacial tissue engineering. Adv. Drug Deliv. Rev. 59, 308–324. ()

    Not in our library10.1016/j.addr.2007.03.019

  9. 9.

    Willerth S. M. Sakiyama-Elbert S. E. 2007 Approaches to neural tissue engineering using scaffolds for drug delivery. Adv. Drug Deliv. Rev. 59, 325–338. ()

    Not in our library10.1016/j.addr.2007.03.014

  10. 10.

    Lee S. H. Shin H. 2007 Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv. Drug Deliv. Rev. 59, 339–359. ()

    Not in our library10.1016/j.addr.2007.03.016

  11. 11.

    Zhang G. Suggs L. J. 2007 Matrices and scaffolds for drug delivery in vascular tissue engineering. Adv. Drug Deliv. Rev. 59, 360–373. ()

    Not in our library10.1016/j.addr.2007.03.018

  12. 12.

    Mouriño V. Boccaccini A. 2010 Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds. J. R. Soc. Interface 7, 209–227. ()

    Not in our library10.1098/rsif.2009.0379

  13. 13.

    Mouriño V. Newby P. Phisbin F. Cattalini P. Lucangioli S. Boccaccini A. R. 2011 Preparation, characterization and in vitro studies of gallium crosslinked alginate/bioactive glass composite films. Soft Matter 7, 6705–6712. ()

    Not in our library10.1039/c1sm05331k

  14. 14.

    Stevens M. 2008 Biomaterials for bone tissue engineering. Mater. Today 11, 18–25. ()

    Not in our library10.1016/s1369-7021(08)70086-5

  15. 15.

    Baroli B. 2009 From natural bone graft to tissue engineering therapeutics: brainstorming on pharmaceutical formulative requirements and challenges. J. Pharm. Sci. 98, 1317–1375. ()

    Not in our library10.1002/jps.21528

  16. 16.

    Rezwan K. Chen Q. Z. Blaker J. J. Boccaccini A. R. 2006 Biodegradable and bioactive porous polymer/metallic composite scaffolds for bone tissue engineering. Biomaterials 27, 3413–3431. ()

    Not in our library10.1016/j.biomaterials.2006.01.039

  17. 17.

    Gielen M. Tiekink E. 2005 Metallotherapeutic drugs and metal-based diagnostic agents: the use of metals in medicine. Chichester, UK: Wiley & Sons (ISBN: 978-0-470-86403-6).

    Not in our library

  18. 18.

    Habibovic P. Barralet J. E. 2011 Bioinorganics and biomaterials: bone repair. Acta Biomater. 7, 3013–3026. ()

    Not in our library10.1016/j.actbio.2011.03.027

  19. 19.

    Gérard C. Bordeleau L. J. Barralet J. Doillon C. J. 2010 The stimulation of angiogenesis and collagen deposition by copper. Biomaterials 31, 824–831.

    Not in our library10.1016/j.biomaterials.2009.10.009

  20. 20.

    Taylor A. 1985 Therapeutic uses of trace elements. Clin. Endocrinol. Metab. 14, 703–724. ()

    Not in our library10.1016/s0300-595x(85)80013-x

  21. 21.

    Jie X. W. Li X. W. Zhi H. W. Jian F. C. 2006 Immobilization of silver on hollow silica nanospheres and nanotubes and their antibacterial effects. Mater. Chem. Phys. 96, 90–97. ()

    Not in our library10.1016/j.matchemphys.2005.06.045

  22. 22.

    Garza M. R. Olguin M. T. Sosa I. G. Alcantara D. Fuentes G. R. 2000 Silver supported on natural Mexican zeolite as an antibacterial material. Microporous Mesoporous Mater. 39, 431–444. ()

    Not in our library10.1016/s1387-1811(00)00217-1

  23. 23.

    Kim T. N. Feng Q. L. Kim J. O. Wu J. Wang H. Chen G. C. Cui F. Z. 1998 Antimicrobial effects of metal ions (Ag+, Cu2+, Zn2+) in hydroxyapatite. J. Mater. Sci. Mater. Med. 9, 129–134. ()

    Not in our library10.1023/a:1008811501734

  24. 24.

    Kawashita M. Tsuneyama S. Miyaji F. Kokubo T. Kozuka H. Yamamoto K. 2000 Antibacterial silver-containing silica glass prepared by sol–gel method. Biomaterials 21, 393–398. ()

    Not in our library10.1016/s0142-9612(99)00201-x

  25. 25.

    Soo J. P. Yu S. J. 2003 Preparation and characterization of activated carbon fibers supported with silver metal for antibacterial behavior. J. Colloid Interface Sci. 261, 238–243. ()

    Not in our library10.1016/s0021-9797(03)00083-3

  26. 26.

    Dubas S. T. Kumlangdudsana P. Potiyara P. 2006 Layer-by-layer deposition of antimicrobial silver nanoparticles on textile fibers. Colloid Surf. A 289, 105–109. ()

    Not in our library10.1016/j.colsurfa.2006.04.012

  27. 27.

    Rupp M. E. Fitzgerald T. Marion N. Helget V. Puumala S. Anderson J. R. Fey P. D. 2004 Effect of silver-coated urinary catheters: efficacy, cost-effectiveness, and antimicrobial resistance. Am. J. Infect. Control 32, 445–450. ()

    Not in our library10.1016/j.ajic.2004.05.002

  28. 28.

    Volker A. Thorsten B. Peter S. Michael W. Peter S. Elvira D. Eugen D. Reinhard S. 2004 An in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. Biomaterials 25, 4383–4391. ()

    Not in our library10.1016/j.biomaterials.2003.10.078

  29. 29.

    Dueland R. Sparado J. A. Rahn B. A. 1982 Silver antibacterial bone cement. Clin. Orthop. Relat. Res. 169, 264–268.

    Not in our library

  30. 30.

    Yamamoto K. Ohashi S. Aono M. Kokubo T. Yamada I. Yamauchi J. 1996 Antibacterial activity of silver ions implanted in filler on oral streptococci. Dent. Mater. 12, 227–229.

    Not in our library10.1016/s0109-5641(96)80027-3

  31. 31.

    Blaker J. J. Nazhat S. N. Boccaccini A. R. 2004 Development and characterisation of silverdoped bioactive glasscoated sutures for tissue engineering and wound healing applications. Biomaterials 25, 1319–1329. ()

    Not in our library10.1016/j.biomaterials.2003.08.007

  32. 32.

    Hoppe A. Guldal N. Boccaccini A. R. 2011 Biological response to ionic dissolution products from bioactive glass and glass–ceramics in the context of bone tissue engineering. Biomaterials 32, 2757–2774. ()

    Not in our library10.1016/j.biomaterials.2011.01.004

  33. 33.

    Wataha J. C. Hobbs D. T. Wong J. J. Dogan S. Zhang H. Chung K. H. Elvington M. C. 2010 Titanates deliver metal ions to human monocytes. J. Mater. Sci. Mater. Med. 21, 1289–1295. ()

    Not in our library10.1007/s10856-009-3941-8

  34. 34.

    Davis R. R. Hobbs D. T. Kahshaba R. Sehkar P. Seta F. N. Messer R. L. Lewis J. B. Wataha J. C. 2010 Titanate particles as agents to deliver gold compounds to fibroblasts and monocytes. J. Biomed. Mater. Res. A 93, 864–869.

    Not in our library10.1002/jbm.a.32407

  35. 35.

    Wataha J. C. Hobbs D. T. Lockwood P. E. Davis R. R. Elvington M. Lewis J. B. Messer R. L. W. 2009 Peroxotitanates for biodelivery of metals. J. Biomed. Mater. Res. B 91, 489–496. ()

    Not in our library10.1002/jbm.b.31402

  36. 36.

    Davis R. R. Lockwood P. E. Hobbs D. T. Messer R. L. W. Price R. J. Lewis J. B. Wataha J. C. 2007 In vitro biological effects of sodium titanate materials. J. Biomed. Mater. Res. B 83, 505–511. ()

    Not in our library10.1002/jbm.b.30823

  37. 37.

    Nyman M. Hobbs D. T. 2006 A family of peroxo-titanate materials tailored for optimal strontium and actinide sorption. Chem. Mater. 18, 6425–6435. ()

    Not in our library10.1021/cm061797h

  38. 38.

    Goka T. J. Stevenson R. E. Hefferan P. M. Howello R. 1976 Menkes disease: a biochemical abnormality in cultured human fibroblast. Proc. Natl Acad. Sci. USA 73, 604–606. ()

    Not in our library10.1073/pnas.73.2.604

  39. 39.

    Lutsenko S. 2008 Metal metabolism: transport, development and neurodegeneration. Biochem. Soc. Trans. 36, 1233–1238. ()

    Not in our library10.1042/bst0361233

  40. 40.

    Milman N. Pedersen P. Steig T. Melsen G. V. 2003 Frequencies of the hereditary hemochromatosis allele in different populations. Comparison of previous phenotypic methods and novel genotypic methods. Int. J. Hematol. 77, 48–54. ()

    Not in our library10.1007/bf02982602

  41. 41.

    Thompson K. Orvig C. 2003 Boon and bane of metal ions in medicine. Science 300, 936–939. ()

    Not in our library10.1126/science.1083004

  42. 42.

    Rosenstein E. D. Caldwell J. R. 1999 Trace elements in the treatment of rheumatic conditions. Rheum. Dis. Clin. North Am. 25, 929–935. ()

    Not in our library10.1016/s0889-857x(05)70111-3

  43. 43.

    Saltman P. D. Strause L. G. 1993 The role of trace minerals in osteoporosis. J. Am. Coll. Nutr. 12, 384–389.

    Not in our library10.1080/07315724.1993.10718327

  44. 44.

    Beattie J. H. Avenell A. 1992 Trace element nutrition and bone metabolism. Nutr. Res. Rev. 5, 167–188. ()

    Not in our library10.1079/nrr19920013

  45. 45.

    Nielsen F. 1990 New essential trace elements for the life sciences. Biol. Trace Elem. Res. 26–27, 599–611. ()

    Not in our library10.1007/bf02992716

  46. 46.

    Cadosch D. Chan E. Gautschi O. P. Filgueira L. 2009 Metal is not inert: role of metal ions released by biocorrosion in aseptic loosening: current concepts. J. Biomed. Mater. Res. A 91, 1252–1262. ()

    Not in our library10.1002/jbm.a.32625

  47. 47.

    Huber M. Reinisch G. Trettenhahn G. Zweymuller K. Lintner F. 2009 Presence of corrosion products and hypersensitivity-associated reactions in periprosthetic tissue after aseptic loosening of total hip replacements with metal bearing surfaces. Acta Biomater. 5, 172–180. ()

    Not in our library10.1016/j.actbio.2008.07.032

  48. 48.

    Guindy J. S. Schiel H. Schmidi F. Wirz J. 2004 Corrosion at the marginal gap of implant-supported suprastructures and implant failure. Int. J. Oral Maxillofac. Implants 19, 826–831.

    Not in our library

  49. 49.

    Rutherford J. C. Bird A. J. 2004 Metal-responsive transcription factors that regulate iron, zinc, and copper homeostasis in eukaryotic cells. Eukaryot Cell 3, 1–13. ()

    Not in our library10.1128/ec.3.1.1-13.2004

  50. 50.

    Barralet J. Gbureck U. Habibovic P. Vorndran E. Gerard C. Doillon C. J. 2009 Angiogenesis in calcium phosphate scaffolds by metallic copper ion release. Tissue Eng. A 15, 1601–1609.

    Not in our library10.1089/ten.tea.2007.0370

  51. 51.

    Di Nunzio S. Verné E. 2005 Process for the production of silver-containing prosthetic devices. PCT/EP2005/056391.

    Not in our library

  52. 52.

    Thompson K. Orvig C. 2000 Design of vanadium compounds as insulin enhancing agents. J. Chem. Soc. Dalton Trans. 2000, 2885–2892. ()

    Not in our library10.1039/b002753g

  53. 53.

    Murphy W. L. Dennis R. G. Kileny J. L. Mooney D. J. 2002 Salt fusion: an approach to improve pore interconnectivity within tissue engineering scaffolds. Tissue Eng. 8, 43–52. ()

    Not in our library10.1089/107632702753503045

  54. 54.

    Cabañas M. V. Peña J. Román J. Vallet-Regí M. 2009 Tailoring vancomycin release from β-TCP/agarose scaffolds. Eur. J. Pharm. Sci. 37, 249–256. ()

    Not in our library10.1016/j.ejps.2009.02.011

  55. 55.

    Zhang Y. Zhang M. 2002 Calcium phosphate/chitosan composite scaffolds for controlled in vitro antibiotic drug release. J. Biomed. Mater. Res. 62, 378–386. ()

    Not in our library10.1002/jbm.10312

  56. 56.

    Mooney D. J. Baldwin D. F. Suh N. P. Vacanti J. P. Langer R. 1996 Novel approach to fabricate porous sponges of poly(D,L-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials 17, 1417–1422. ()

    Not in our library10.1016/0142-9612(96)87284-x

  57. 57.

    Harris L. D. Kim B. Mooney D. J. 1998 Open pore biodegradable matrices formed with gas foaming. J. Biomed. Mater. Res. 42, 396–402.

    Not in our library10.1002/(sici)1097-4636(19981205)42:3<396::aid-jbm7>3.0.co;2-e

  58. 58.

    Vitale-Brovarone C. Miola M. Balagna C. Verné E. 2008 3D-glass–ceramic scaffolds with antibacterial properties for bone grafting. Chem. Eng. J. 137, 129–136. ()

    Not in our library10.1016/j.cej.2007.07.083

  59. 59.

    Chen W. Liu Y. Courtney H. S. Bettenga M. Agrawal C. M. Bumgardner J. D. Ong J. L. 2006 In vitro anti-bacterial and biological properties of magnetron co-sputtered silver-containing hydroxyapatite coating. Biomaterials 27, 5512–5517. ()

    Not in our library10.1016/j.biomaterials.2006.07.003

  60. 60.

    Jones J. Ehrenfried L. M. Saravanapavan P. Hench L. 2006 Controlling ion release from bioactive glass foam scaffolds with antibacterial properties. J. Mater. Sci. Mater. Med. 17, 989–996. ()

    Not in our library10.1007/s10856-006-0434-x

  61. 61.

    Domingues Z. R. Cortés M. E. Gomes T. A. Diniz H. F. Freitas C. S. Gomes J. B. Fariac A. M. Sinisterra R. D. 2004 Bioactive glass as a drug delivery system of tetracycline and tetracycline associated with β-cyclodextrin. Biomaterials 25, 327–333.

    Not in our library10.1016/s0142-9612(03)00524-6

  62. 62.

    Kimakhe S. Bohic S. Larosse C. Reynaud A. Pilet P. Giumelli B. Heymann D. Daculsi G. 1999 Biological activities of sustained polymixin B release from calcium phosphate biomaterial prepared by dynamic compaction: an in vitro study. J. Biomed. Mater. Res. 47, 18–27.

    Not in our library10.1002/(sici)1097-4636(199910)47:1<18::aid-jbm3>3.0.co;2-t

  63. 63.

    Vallet-Regi M. Salinas A. J. Roman J. Gil M. 1999 Effect of magnesium content on the in vitro bioactivity of CaO–MgO–SiO2–P2O5 sol–gel glasses. J. Mater. Chem. 9, 515–518. ()

    Not in our library10.1039/a808679f

  64. 64.

    Miyai T. Ito A. Tamazawa G. Matsuno T. Sogo Y. Nakamura C. Yamazaki A. Satoh T. 2008 Antibiotic-loaded poly-ɛ-caprolactone and porous β-tricalcium phosphate composite for treating osteomyelitis. Biomaterials 29, 350–358.

    Not in our library10.1016/j.biomaterials.2007.09.040

  65. 65.

    Castro C. Évora C. Baro M. Soriano I. Sánchez E. 2005 Two-month ciprofloxacin implants for multibacterial bone infections. Eur. J. Pharm. Sci. 60, 401–406.

    Not in our library10.1016/j.ejpb.2005.02.005

  66. 66.

    Chua C. K. Leong K. F. Tan K. H. Wiria F. E. Cheah C. M. 2004 Development of tissue scaffolds using selective laser sintering of polyvinyl alcohol/hydroxyapatite biocomposite for craniofacial and joint defects. J. Mater. Sci. Mater. Med. 15, 1112–1113. ()

    Not in our library10.1023/b:jmsm.0000046393.81449.a5

  67. 67.

    Ciardelli G. Chiono V. Cristallini C. Barbani N. Ahluwalia A. Vozzi G. Previti A. Tantussi G. Giusti P. 2004 Innovative tissue engineering structures through advanced manufacturing technologies. J. Mater. Sci. Mater. Med. 15, 305–310. ()

    Not in our library10.1023/b:jmsm.0000021092.03087.d4

  68. 68.

    Cooke M. N. Fisher J. P. Dean D. Rimnac C. Mikos A. G. 2003 Use of stereolithography to manufacture critical-sized 3D biodegradable scaffolds for bone ingrowth. J. Biomed. Mater. Res. B 64, 65–69. ()

    Not in our library10.1002/jbm.b.10485

  69. 69.

    Dhariwala B. Hunt E. Boland T. 2004 Rapid prototyping of tissue-engineering constructs, using photopolymerizable hydrogels and stereolithography. Tissue Eng. 10, 1316–1322.

    Not in our library10.1089/ten.2004.10.1316

  70. 70.

    Fisher J. P. Vehof J. W. Dean D. Van der Waerde J. P. Holland T. A. Mikos A. G. Jansen J. A. 2002 Soft and hard tissue response to photocrosslinked poly(propylene fumarate) scaffolds in a rabbit model. J. Biomed. Mater. Res. 59, 547–556.

    Not in our library10.1002/jbm.1268

  71. 71.

    Sodian R. Loebe M. Hein A. Martin D. P. Hoerstrup S. P. Potapov E. V. Hausmann H. Lueth T. Hetzer R. 2002 Application of stereolithography for scaffold fabrication for tissue engineered heart valves. ASAIO J. 48, 12–16. ()

    Not in our library10.1097/00002480-200201000-00004

  72. 72.

    Tan S. H. Inai R. Kotaki M. Ramakrishna S. 2005 Systematic parameter study for ultra-fine fiber fabrication via electrospinning process. Polymer 46, 6128–6134. ()

    Not in our library10.1016/j.polymer.2005.05.068

  73. 73.

    Giordano R. A. Wu B. M. Borland S. W. Cima L. G. Sachs E. M. Cima M. J. 1996 Mechanical properties of dense polylactic acid structures fabricated by three dimensional printing. J. Biomater. Sci. Polym. 8, 63–75. ()

    Not in our library10.1163/156856297x00588

  74. 74.

    Landers R. Hubner U. Schmelzeisen R. Mulhaupt R. 2002 Rapid prototyping of scaffolds derived from thermoreversible hydrogels and tailored for applications in tissue engineering. Biomaterials 23, 4437–4447. ()

    Not in our library10.1016/s0142-9612(02)00139-4

  75. 75.

    Teo W.-E. He W. Ramakrishna S. 2006 Electrospun scaffold tailored for tissue-specific extracellular matrix. Biotechnol. J. 1, 918–929. ()

    Not in our library10.1002/biot.200600044

  76. 76.

    Kidoaki S. Kuen K. II Matsuda T. 2005 Mesoscopic spatial designs of nano- and microfiber meshes for tissue-engineering matrix and scaffold based on newly devised multilayering and mixing electrospinning techniques. Biomaterials 26, 37–46. ()

    Not in our library10.1016/j.biomaterials.2004.01.063

  77. 77.

    Tan K. H. Chua C. K. Leong K. F. Cheah C. M. Gui W. S. Tan W. S. Wiria F. E. 2005 Selective laser sintering of biocompatible polymers for applications in tissue engineering. Biomed. Mater. Eng. 15, 113–124.

    Not in our library

  78. 78.

    Bose S. Darsell J. Hosick H. Yang L. Sarkar D. Bandyopadhyay A. 2002 Processing and characterization of porous alumina scaffolds. J. Mater. Sci. Mater. Med. 13, 23–28. ()

    Not in our library10.1023/a:1013622216071

  79. 79.

    Hutmacher D. Schantz T. Zein I. Ng K. W. Teoh S. H. Tan K. C. 2001 Mechanical properties and cell cultural response of polycaprolactone scaffolds designed and fabricated via fused deposition modelling. J. Biomed. Mater. Res 55, 203–216. ()

    Not in our library10.1002/1097-4636(200105)55:2<203::aid-jbm1007>3.0.co;2-7

  80. 80.

    Khalil S. Nam J. Sun W. 2005 Multi-nozzle deposition for construction of 3D biopolymer tissue scaffolds. Rapid Prototyping J. 11, 9–17. ()

    Not in our library10.1108/13552540510573347

  81. 81.

    Hutmacher D. 2000 Scaffolds in tissue engineering bone and cartilage. Biomaterials 21, 2529–2543. ()

    Not in our library10.1016/s0142-9612(00)00121-6

  82. 82.

    Hutmacher D. Sittinger M. Risbud M. V. 2004 Scaffold-based tissue engineering: rationale for computer-aided design and solid free-form fabrication systems. Trends Biotechnol. 22, 354–362. ()

    Not in our library10.1016/j.tibtech.2004.05.005

  83. 83.

    Leong K. F. Cheah C. M. Chua C. K. 2003 Solid freeform fabrication of three-dimensional scaffolds for engineering replacement tissues and organs. Biomaterials 24, 2363–2378. ()

    Not in our library10.1016/s0142-9612(03)00030-9

  84. 84.

    Moroni L. de Wijn J. R. Van Blitterswijk C. A. 2008 Integrating novel technologies to fabricate smart scaffolds. J. Biomater. Sci. Polym. Ed. 19, 543–572. ()

    Not in our library10.1163/156856208784089571

  85. 85.

    Sachlos E. Czernuszka J. T. 2003 Making scaffolds work: a review on the application of solid freeform fabrication technology to the production of tissue engineering scaffolds. Eur. Cell Mater. 5, 29–40.

    Not in our library10.22203/ecm.v005a03

  86. 86.

    Tsang V. L. Bhatia S. N. 2004 Three dimensional tissue fabrication. Adv. Drug Deliv. 56, 1635–1647. ()

    Not in our library10.1016/j.addr.2004.05.001

  87. 87.

    Yeong W. Y. Chua C. K. Leong K. F. Chandrasekaran M. 2004 Rapid prototyping in tissue engineering: challenges and potential. Trends Biotechnol. 22, 643–652. ()

    Not in our library10.1016/j.tibtech.2004.10.004

  88. 88.

    Hollister S. 2005 Porous scaffold design for tissue engineering. Nat. Mat. 4, 518–524. ().

    Not in our library10.1038/nmat1421

  89. 89.

    Soundrapandian C. Sa B. Datta S. 2009 Organic–inorganic composites for bone drug delivery. AAPS Pharm. Sci. Tech. 10, 1158–1171. ()

    Not in our library10.1208/s12249-009-9308-0

  90. 90.

    Hench L. L. 1998 Bioceramics. J. Am. Ceram. Soc. 81, 1705–1728. ()

    Not in our library10.1111/j.1151-2916.1998.tb02540.x

  91. 91.

    Hench L. L. Thompson I. 2010 Twenty-first century challenges for biomaterials. J. R. Soc. Interface 7, 379–391. ()

    Not in our library10.1098/rsif.2010.0151.focus

  92. 92.

    Wilson J. Low S. B. 1992 Bioactive ceramics for periodontal treatment: comparative studies. J. Appl. Biomater. 3, 123–169. ()

    Not in our library10.1002/jab.770030208

  93. 93.

    Hench L. L. Xynos I. D. Buttery L. D. Polak J. M. 2000 Bioactive materials to control cell cycle. J. Mater. Res. Innov. 3, 313–323. ()

    Not in our library10.1007/s100190000055

  94. 94.

    Xynos I. D. Edgar A. J. Buttery D. K. L. Hench L. L. Polak J. M. 2000 Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein synthesis. Biochem. Biophys. Res. Commun. 276, 461–465. ()

    Not in our library10.1006/bbrc.2000.3503

  95. 95.

    Xynos I. D. Edgar A. J. Buttery D. K. L. Hench L. L. Polak J. M. 2001 Gene-expression profiling of human osteoblasts following treatment with the ionic products of bioglass (R) 45S5 dissolution. J. Biomed. Mater. Res. 55, 151–157. ()

    Not in our library10.1002/1097-4636(200105)55:2<151::aid-jbm1001>3.0.co;2-d

  96. 96.

    Bielby R. C. Christodoulou I. S. Pryce R. S. Radford W. J. P. Hench L. L. Polak J. M. 2004 Time- and concentration-dependent effects of dissolution products of 58S sol–gel bioactive glass on proliferation and differentiation of murine and human osteoblasts. Tissue Eng. 10, 1018–1026. ().

    Not in our library10.1089/ten.2004.10.1018

  97. 97.

    Bielby R. C. Pryce R. S. Hench L. L. Polak J. M. 2005 Enhanced derivation of osteogenic cells from murine embryonic stem cells after treatment with ionic dissolution products of 58S bioactive sol–gel glass. Tissue Eng. 11, 479–488. ().

    Not in our library10.1089/ten.2005.11.479

  98. 98.

    Gough J. E. Jones J. R. Hench L. L. 2004 Nodule formation and mineralisation of human primary osteoblasts cultured on a porous bioactive glass scaffold. Biomaterials 25, 2039–2046. ()

    Not in our library10.1016/j.biomaterials.2003.07.001

  99. 99.

    Christodoulou I. Buttery L. D. K. Saravanapavan P. Tai G. P. Hench L. L. Polak J. M. 2005 Dose- and time-dependent effect of bioactive gel-glass ionic-dissolution products on human fetal osteoblast-specific gene expression. J. Biomed. Mater. Res. B 74, 529–537. ()

    Not in our library10.1002/jbm.b.30249

  100. 100.

    Christodoulou I. Buttery L. D. K. Saravanapavan P. Tai G. P. Hench L. L. Polak J. M. 2005 Characterization of human foetal osteoblasts by microarray analysis following stimulation with 58S bioactive gel-glass ionic dissolution products. J. Biomed. Mater. Res. B 77, 431–446. ()

    Not in our library10.1002/jbm.b.30455

  101. 101.

    Day R. M. Boccaccini A. R. Shurey S. Roether J. A. Forbes A. Hench L. L. Gabe S. M. 2004 Assessment of polyglycolic acid mesh and bioactive glass for soft-tissue engineering scaffolds. Biomaterials 25, 5857–5866. ()

    Not in our library10.1016/j.biomaterials.2004.01.043

  102. 102.

    Hench L. L. Polak J. 2002 Third-generation biomedical materials. Science 8, 1014–1017. ()

    Not in our library10.1126/science.1067404

  103. 103.

    Gorustovich A. A. Roether J. A. Boccaccini A. R., 2010 Effect of bioactive glasses on angiogenesis: a review of in vitro and in vivo evidences. Tissue Eng. B 16, 199–207.

    Not in our library10.1089/ten.teb.2009.0416

  104. 104.

    Yun Y. 2009 Revolutionizing biodegradable metals. Materials Today 12, 22–32. ()

    Not in our library10.1016/s1369-7021(09)70273-1

  105. 105.

    Witte F. Feyerabend F. Maier P. Fischer J. Störmer M. Blawert C. Dietzel W. Hort N. 2007 Biodegradable magnesium–hydroxyapatite metal matrix composites. Biomaterials 28, 2163–2174. ()

    Not in our library10.1016/j.biomaterials.2006.12.027

  106. 106.

    Yun Y. H. 2008 Nanotube electrodes and biosensors: review. NanoToday 2, 30–38.

    Not in our library

  107. 107.

    Shanov V. 2008 UC 108-091 invention disclosure composition and method for producing magnesium based biodegradable composite implants. Chichester, UK: John Wiley & Sons Ltd.

    Not in our library

  108. 108.

    Mast D. Shanov V. Jayasinghe C. Schulz M. 2008 UC 109-035, invention disclosure ‘use of carbon nanotube thread, ribbon, and arrays for the transmission and reception of electromagnetic signals and radiation’. Chichester, UK: John Wiley & Sons Ltd.

    Not in our library

  109. 109.

    Schulz M. J 2009 UC 109-085, invention disclosure corrosion measurement for biodegradable metal implants. Chichester, UK: John Wiley & Sons Ltd.

    Not in our library

  110. 110.

    Schulz M. J. Shanov V. N. Sankar J. Witte F. Wagner W. Borovetz H. Kumta P. Sfeir C. 2009 UC 109-111 invention disclosure permanent and biodegradable responsive implants that expand and adapt to the human body. Chichester, UK: John Wiley & Sons Ltd.

    Not in our library

  111. 111.

    Shanov V. 2009 UC 109-089 invention disclosure composition and method for magnesium biodegradable material for medical implant applications. Chichester, UK: John Wiley & Sons Ltd.

    Not in our library

  112. 112.

    Denkena B. Lucas A. 2007 Biocompatible magnesium alloys as absorbable implant materials: adjusted surface and subsurface properties by machining processes. Ann. CIRP (CIRP Ann. Manuf. Technol.) 56, 113–116. ()

    Not in our library10.1016/j.cirp.2007.05.029

  113. 113.

    Yun Y. H. Dong Z. Shanov V. N. Schulz M. J. 2007 Electrochemical impedance measurement of prostate cancer cells using carbon nanotube array electrodes in a microfluidic channel. Nanotechnology 18, 465505 ()

    Not in our library10.1088/0957-4484/18/46/465505

  114. 114.

    Machida-Sano I. Matsuda Y. Namiki H. 2009 In vitro adhesion of human dermal fibroblasts on iron cross-linked alginate films. Biomed. Mater. 4, 25 008–25 016. ()

    Not in our library10.1088/1748-6041/4/2/025008

  115. 115.

    Bohner M. 2009 Silicon-substituted calcium phosphates: a critical view. Biomaterials 30, 6403–6406. ()

    Not in our library10.1016/j.biomaterials.2009.08.007

  116. 116.

    Mouriño V. Newby P. Boccaccini A. R. 2010 Preparation and characterisation of gallium releasing 3-D alginate coated 45S5 bioglass based scaffolds for bone tissue engineering. Adv. Eng. Mater. Biomater. 12, B283–B291. ()

    Not in our library10.1002/adem.200980078

  117. 117.

    Abou Neel E. A. Chrzanowski W. Pickup D. M. O'dell L. A. Mordan N. J. Newport R. J. Smith M. E. Knowles J. C. 2010 Structure and properties of strontium-doped phosphate-based glasses. J. R. Soc. Interface 6, 435–446. ()

    Not in our library10.1098/rsif.2008.0348

  118. 118.

    Pickup D. M. Moss R. M. Qiu D. Newport R. J. Valappil S. P. Knowles J. C. Smith M. E. 2009 Structural characterization by X-ray methods of novel antimicrobial gallium-doped phosphate-based glasses. J. Chem. Phys. 130, 1–7. ()

    Not in our library10.1063/1.3076057

  119. 119.

    Lankford K. Letourneau P. 1989 Evidence that calcium may control neurite outgrowth by regulating the stability of actin filaments. J. Cell Biol. 109, 1229–1243. ()

    Not in our library10.1083/jcb.109.3.1229

  120. 120.

    Bolsover S. R. 2005 Calcium signalling in growth cone migration. Cell Calcium 37, 395–402. ()

    Not in our library10.1016/j.ceca.2005.01.007

  121. 121.

    Konur S. Ghosh A. 2005 Calcium signalling and the control of dendritic development. Neuron 46, 401–405. ()

    Not in our library10.1016/j.neuron.2005.04.022

  122. 122.

    Bunting S. Di Silvio L. Deb S. Hall S. 2005 Bioresorbable glass fibres facilitate peripheral nerve regeneration. J. Hand Surg. Eur. 30, 242–247. ()

    Not in our library10.1016/j.jhsb.2004.11.003

  123. 123.

    Zhou H. Wei J. Wu X. Shi J. Liu C. Jia J. Dai C. Gan Q. I. 2010 The bio-functional role of calcium in mesoporous silica xerogels on the responses of osteoblasts in vitro. J. Mater. Sci. Mater. Med. 21, 2175–2185. ()

    Not in our library10.1007/s10856-010-4083-8

  124. 124.

    Maeno S. Niki Y. Matsumoto H. Morioka H. Yatabe T. Funayama A. Toyama Y. Taguchi T. Tanaka J. 2005 The effect of calcium ion concentration on osteoblast viability, proliferation and differentiation in monolayer and 3D culture. Biomaterials 26, 4847–4855. ()

    Not in our library10.1016/j.biomaterials.2005.01.006

  125. 125.

    Marie J. P. 2010 The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46, 571–576. ()

    Not in our library10.1016/j.bone.2009.07.082

  126. 126.

    Valerio P. Pereira M. M. Goes A. M. Leite M. F. 2009 Effects of extracellular calcium concentration on the glutamate release by bioactive glass (BG60S) preincubated osteoblasts. Biomed. Mater. 4, 045011 ()

    Not in our library10.1088/1748-6041/4/4/045011

  127. 127.

    Hinoi E. Takarada T. Yoneda Y. 2004 Glutamate signaling system in bone. J. Pharmacol. Sci. 94, 215–220. ()

    Not in our library10.1254/jphs.94.215

  128. 128.

    Kawamura H. Ito A. Miyakawa S. Layrolle P. Ojima K. Ichinose N. Tateishi T. 2000 Stimulatory effect of zinc-releasing calcium phosphate implant on bone formation in rabbit femora. J. Biomed. Mater. Res. 50, 184–190. ()

    Not in our library10.1002/(sici)1097-4636(200005)50:2<184::aid-jbm13>3.0.co;2-3

  129. 129.

    Fan W. Crawford R. Xiao Y. 2010 Enhancing in vivo vascularized bone formation by cobalt chloride-treated bone marrow stromal cells in a tissue engineered periosteum model. Biomaterials 31, 3580–3589. ()

    Not in our library10.1016/j.biomaterials.2010.01.083

  130. 130.

    Storrie H. Stupp S. I. 2005 Cellular response to zinc-containing organoapatite: an in vitro study of proliferation, alkaline phosphatase activity and biomineralisation. Biomaterials 26, 5492–5499. ()

    Not in our library10.1016/j.biomaterials.2005.01.043

  131. 131.

    Wu X. Itoh N. Taniguchi T. Nakanishi T. Tatsu Y. Yumoto N. Tanaka K. 2003 Zinc-induced sodium-dependent vitamin C transporter 2 expression: potent roles in osteoblast differentiation. Arch. Biochem. Biophys. 420, 114–120. ()

    Not in our library10.1016/j.abb.2003.09.013

  132. 132.

    Ohnishi S. Yasuda T. Kitamura S. Nagaya N. 2007 Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells 25, 1166–1177. ()

    Not in our library10.1634/stemcells.2006-0347

  133. 133.

    Loboda A. Jazwa A. Wegiel B. Jozkowicz A. Dulak J. 2005 Heme oxygenase-1-dependent and -independent regulation of angiogenic genes expression: effect of cobalt protoporphyrin and cobalt chloride on VEGF and IL-8 synthesis in human microvascular endothelial cells. Cell Mol. Biol. 51, 347–355.

    Not in our library

  134. 134.

    Hu G. F. 1998 Copper stimulates proliferation of human endothelial cells under culture. J. Cell Biochem. 69, 326–335. ()

    Not in our library10.1002/(sici)1097-4644(19980601)69:3<326::aid-jcb10>3.0.co;2-a

  135. 135.

    Munthe E. Aaseth J. Jellum E. 1986 Trace elements and rheumatoid arthritis (RA)–pathogenetic and therapeutic aspects. Acta Pharmacol. Toxicol. (Copenh) 59, 365–373. ()

    Not in our library10.1111/j.1600-0773.1986.tb02781.x

  136. 136.

    Arredondo M. Nunez M. T. 2005 Iron and copper metabolism. Mol. Aspects Med. 26, 313–327. ()

    Not in our library10.1016/j.mam.2005.07.010

  137. 137.

    Linder M. C. Hazegh-Azam M. 1996 Copper biochemistry and molecular biology. Am. J. Clin. Nutr. 63, 797S–811S.

    Not in our library10.1093/ajcn/63.5.797

  138. 138.

    Collery P. Keppler B. Madoulet C. Desoize B. 2002 Gallium in cancer treatment. Crit. Rev. Oncol. Hematol. 42, 283–296. ()

    Not in our library10.1016/s1040-8428(01)00225-6

  139. 139.

    Rodríguez P. Ríos S. González M. 2002 Modulation of the proliferation and differentiation of human mesenchymal stem cells by copper. J. Cell. Biochem. 85, 92–100. ()

    Not in our library10.1002/jcb.10111

  140. 140.

    Bar-Or D. Thomas G. W. Yukl R. L. Rael L. T. Shimonkevitz R. P. Curtis C. G. Winkler J. V. 2003 Copper stimulates the synthesis and release of interleukin-8 in human endothelial cells: a possible early role in systemic inflammatory responses. Shock 20, 154–158. ()

    Not in our library10.1097/01.shk.0000068318.49350.3a

  141. 141.

    Abou Neel E. A. Ahmed I. Pratten J. Nazhat S. N. Knowles J. C. 2005 Characterisation of antibacterial copper releasing degradable phosphate glass fibres. Biomaterials 26, 2247–2254. ()

    Not in our library10.1016/j.biomaterials.2004.07.024

  142. 142.

    Barbucci R. Lamponi S. Magnani A. Piras F. M. Rossi A. Weber E. 2005 Role of the Hyal-Cu(II) complex on bovine aortic and lymphatic endothelial cells behaviour on microstructured surfaces. Biomacromolecules 6, 212–219. ()

    Not in our library10.1021/bm049568g

  143. 143.

    Giavaresi G. Torricelli P. Fornasari P. M. Giardino R. Barbucci R. Leone G. 2005 Blood vessel formation after soft-tissue implantation of hyaluronan-based hydrogel supplemented with copper ions. Biomaterials 26, 3001–3008. ()

    Not in our library10.1016/j.biomaterials.2004.08.027

  144. 144.

    Feng W. Ye F. Xue W. Zhou Z. Kang Y. J. 2009 Copper regulation of hypoxia-inducible factor-1 activity. Mol. Pharmacol. 75, 174–182. ()

    Not in our library10.1124/mol.108.051516

  145. 145.

    Rajalingam D. Kumar T. K. Yu C. 2005 The C2A domain of synaptotagmin exhibits a high binding affinity for copper: implications in the formation of the multiprotein FGF release complex. Biochemistry 44, 14 431–14 442. ()

    Not in our library10.1021/bi051387r

  146. 146.

    Gérard C. Bordeleau L. J. Barralet J. Doillon Ch. J. 2010 The stimulation of angiogenesis and collagen deposition by copper. Biomaterials 31, 824–831. ()

    Not in our library10.1016/j.biomaterials.2009.10.009

  147. 147.

    Borkow G. Gabbay J. Zatcoff R. 2008 Could chronic wounds not heal due to too low local copper levels? Med. Hypotheses 70, 610–613. ()

    Not in our library10.1016/j.mehy.2007.06.006

  148. 148.

    Hu G. F. 1998 Copper stimulates proliferation of human endothelial cells under culture. J. Cell. Biochem. 69, 326–335.

    Not in our library10.1002/(sici)1097-4644(19980601)69:3<326::aid-jcb10>3.0.co;2-a

  149. 149.

    Sen C. K. Khanna S. Venojarvi M. Trikha P. Ellison E. C. Hunt T. K. Roy S. 2002 Copper induced vascular endothelial growth factor expression and wound healing. Am. J. Physiol. Heart Circ. Physiol. 282, H1821–H1827.

    Not in our library10.1152/ajpheart.01015.2001

  150. 150.

    Parke A. Bhattacherjee P. Palmer R. M. Lazarus N. R. 1998 Characterization and quantification of copper sulphate induced vascularization of the rabbit cornea. Am. J. Pathol. 130, 173–178.

    Not in our library

  151. 151.

    Warrell R. P. Bosco B. Weinerman S. Levine B. Lane J. Bockman R. 1990 Gallium nitrate for advanced Paget disease of bone: effectiveness and dose–response analysis. Ann. Intern. Med. 113, 847–851.

    Not in our library10.7326/0003-4819-113-11-847

  152. 152.

    Warrell R. P. Isaacs M. Coonley C. J. Alcock N. W. Bockman R. S. 1985 Metabolic effects of gallium nitrate administered by prolonged infusion. Cancer Treat. Rep. 69, 653–655.

    Not in our library

  153. 153.

    Warrell R. P. Bockman R. S. Coonley C. J. Isaacs M. Staszewski H. 1984 Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J. Clin. Invest. 73, 1487–1490. ()

    Not in our library10.1172/jci111353

  154. 154.

    Bernstein L. R. 1998 Mechanisms of therapeutic activity for gallium. Pharmacol. Rev. 50, 665–682.

    Not in our library

  155. 155.

    Verron E. 2010 Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts. Br. J. Pharmacol. 159, 1681–1692. ()

    Not in our library10.1111/j.1476-5381.2010.00665.x

  156. 156.

    Valappil S. P. 2009 Controlled delivery of antimicrobial gallium ions from phosphate-based glasses. Acta Biomater. 5, 1198–1210. ()

    Not in our library10.1016/j.actbio.2008.09.019

  157. 157.

    Nanami M. 2005 Tumor necrosis factor-α-induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 25, 2495–2501. ()

    Not in our library10.1161/01.atv.0000190610.63878.20

  158. 158.

    Rouault T. A. 2003 How mammals acquire and distribute iron needed for oxygen-based metabolism? PLoS Biol. 1, e79 ()

    Not in our library10.1371/journal.pbio.0000079

  159. 159.

    Ahmed I. Collins C. A. Lewis M. P. Olsen I. Knowles J. C. 2004 Processing, characterisation and biocompatibility of iron-phosphate glass fibres for tissue engineering. Biomaterials 25, 3223–3232. ()

    Not in our library10.1016/j.biomaterials.2003.10.013

  160. 160.

    Rude R. K. Gruber H. E. Norton H. J. Wei L. Y. Frausto A. Mills B. G. 2004 Bone loss induced by dietary magnesium reduction to 10% of the nutrient requirement in rats is associated with increased release of substance P and tumor necrosis factor-alpha. J. Nutr. 134, 79–85.

    Not in our library10.1093/jn/134.1.79

  161. 161.

    Rude R. K. Gruber H. E. Wei L. Y. Frausto A. Mills B. G. 2003 Magnesium deficiency: effect on bone and mineral metabolism in the mouse. Calcif. Tissue Int. 72, 32–41. ()

    Not in our library10.1007/s00223-001-1091-1

  162. 162.

    Hartwig A. 2001 Role of magnesium in genomic stability. Mutat. Res. Fundam. Mol. Mech. Mutagen. 475, 113–121. ()

    Not in our library10.1016/s0027-5107(01)00074-4

  163. 163.

    Yamasaki Y. Yoshida Y. Okazaki M. Shimazu A. Uchida T. Kubo T. 2002 Synthesis of functionally graded MgCO3 apatite accelerating osteoblast adhesion. J. Biomed. Mater. Res. 62, 99–105. ()

    Not in our library10.1002/jbm.10220

  164. 164.

    Yamasaki Y. Yoshida Y. Okazaki M. Shimazu A. Kubo T. Akagawa Y. 2003 Action of FgMgCO3-Ap-collagen composite in promoting bone formation. Biomaterials 24, 4913–4920. ()

    Not in our library10.1016/s0142-9612(03)00414-9

  165. 165.

    Zreiqat H. Howlett C. R. Zannettino A. Evans P. Schulze-Tanzil G. Knabe C. Shakibaei M. 2002 Mechanisms of magnesium-stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants. J. Biomed. Mater. Res. 62, 175–184. ()

    Not in our library10.1002/jbm.10270

  166. 166.

    Law N. Caudle M. Pecoraro V. 1998 Manganese redox enzymes and model systems: properties, structures, and reactivity. Adv. Metallic Chem. 46, 305–440. ()

    Not in our library10.1016/s0898-8838(08)60152-x

  167. 167.

    Takeda A. 2003 Manganese action in brain function. Brain Res. Rev. 41, 79–87. ()

    Not in our library10.1016/s0165-0173(02)00234-5

  168. 168.

    Westenberg D. 2000 Fighting infections with glass. In Proc. 100th General Meeting of the American Society for Microbiology, 21–25 May 2000, Los Angeles, ASM. Chichester, UK: John Wiley & Sons Ltd.

    Not in our library

  169. 169.

    Wassall M. A. Santin M. Isalberti C. Cannas M. Denyer S. P. 1997 Adhesion of bacteria to stainless steel and silver-coated orthopaedics external fixation pins. J. Biomed. Mater. Res. 36, 325–330. ()

    Not in our library10.1002/(sici)1097-4636(19970905)36:3<325::aid-jbm7>3.0.co;2-g

  170. 170.

    Yoshida K. Tanagawa M. Atsuta M. 1999 Characterization and inhibitory effect of antibacterial dental resin composites incorporating silver-supported materials. J. Biomed. Mater. Res. 47, 516–522. ()

    Not in our library10.1002/(sici)1097-4636(19991215)47:4<516::aid-jbm7>3.0.co;2-e

  171. 171.

    Stanislawsky L. Daniau X. Lautiè A. Goldberg M. 1999 Factors responsible for pulp cell cytotoxicity induced by resin-modified glass ionomer cements. J. Biomed. Mater. Res. (Appl. Biomater.) 48, 277–288. ()

    Not in our library10.1002/(sici)1097-4636(1999)48:3<277::aid-jbm11>3.0.co;2-t

  172. 172.

    Massè A. Bruno A. Bosetti M. Biasibetti A. Cannas M. Gallinaro P. 2000 Prevention of pin track infection in external fixation with silver coated pins: clinical and microbiological results. J. Biomed. Mater. Res. (Appl. Biomater.) 53, 600–604. ()

    Not in our library10.1002/1097-4636(200009)53:5<600::aid-jbm21>3.0.co;2-d

  173. 173.

    Kumon H. Hashimoto H. Nishimura M. Monden K. Ono N. 2001 Catheter-associated urinary tract infections: impact of catheter materials on their management. Int. J. Antimicrob. Agents 17, 311–316. ()

    Not in our library10.1016/s0924-8579(00)00360-5

  174. 174.

    Kraft C. N. Hansis M. Arens S. Menger M. D. Vollmar B. 2000 Striated muscle microvascular response to silver implants: a comparative in vivo study with titanium and stainless steel. J. Biomed. Mater. Res. 49, 192–199. ()

    Not in our library10.1002/(sici)1097-4636(200002)49:2<192::aid-jbm6>3.0.co;2-c

  175. 175.

    Feng Q. L. Wu J. Chen G. Q. Cui F. Z. Kim T. N. Kim J. O. 2000 A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J. Biomed. Mater. Res. 52, 662–668. ()

    Not in our library10.1002/1097-4636(20001215)52:4<662::aid-jbm10>3.0.co;2-3

  176. 176.

    Djokic S. S. Burrel R. E. 1998 Behaviour of silver in physiological solutions. J. Electrochem. Soc. 145, 1426–1430. ()

    Not in our library10.1149/1.1838499

  177. 177.

    Hetrick E. M. Schoenfisch M. H. 2006 Reducing implant-related infections: active release strategies. Chem. Soc. Rev. 35, 780–789. ()

    Not in our library10.1039/b515219b

  178. 178.

    Boivin G. Deloffre P. Perrat B. Panczer G. Boudeulle M. Mauras Y. Allain P. Tsouderos Y. Meunier P. J. 1996 Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S12911) administration. J. Bone Miner. Res. 11, 1302–1311. ()

    Not in our library10.1002/jbmr.5650110915

  179. 179.

    Dahl S. G. Allain P. Marie P. J. Mauras Y. Boivin G. Ammann P. Tsouderos Y. Delmas P. D. Christiansen C. 2001 Incorporation and distribution of strontium in bone. Bone 28, 446–453. ()

    Not in our library10.1016/s8756-3282(01)00419-7

  180. 180.

    Grynpas M. D. Hamilton E. Cheung R. Tsouderos Y. Deloffre P. Hott M. Marie P. J. 1996 Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect. Bone 18, 253–259. ()

    Not in our library10.1016/8756-3282(95)00484-x

  181. 181.

    Marie J. P. Ammann P. Boivin G. Rey C. 2001 Mechanisms of action and therapeutic potential of strontium in bone. Calcif. Tissue Int. 69, 121–129. ()

    Not in our library10.1007/s002230010055

  182. 182.

    Zhu L.-L. Zaidi S. Peng Y. 2007 Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochem. Biophys. Res. Commun. 355, 307–311. ()

    Not in our library10.1016/j.bbrc.2007.01.120

  183. 183.

    Nxumalo F. Glover N. R. Tracey A. S. 1998 Kinetics and molecular modelling studies of the inhibition of protein tyrosine phosphatases by N,N-dimethylhydroxylamine complexes of vanadium (V). J. Biol. Inorg. Chem. 3, 534–542. ()

    Not in our library10.1007/s007750050265

  184. 184.

    Huyer G. Liu S. Kelly J. Moffat J. Payette P. Kennedy B. Tsaprailis G. Gresser M. J. Chidambaram R. 1997 Mechanism of inhibition of protein–tyrosine phosphatases by vanadate and pervanadate. J. Biol. Chem. 272, 843–851. ()

    Not in our library10.1074/jbc.272.2.843

  185. 185.

    Posner B. I. 1994 Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J. Biol. Chem. 269, 4596–4604.

    Not in our library

  186. 186.

    Crans D. C. 1998 Vanadium compounds: chemistry, biochemistry, and therapeutic applications, vol. 711 (eds Tracey A. S. Crans D. C. ), pp. 82–103. Washington, DC: American Chemical Society.

    Not in our library

  187. 187.

    Cuncic C. Detich N. Ethier D. Tracey A. S. Gresser M. J. Ramachandran C. J. 1999 Vanadate inhibition of protein tyrosine phosphatases in Jurkat cells: modulation by redox state. J. Biol. Inorg. Chem. 4, 354–359. ()

    Not in our library10.1007/s007750050322

  188. 188.

    Tracey A. S. 2000 Hydroxamido vanadates: aqueous chemistry and function in protein tyrosine phosphatases and cell cultures. J. Inorg. Biochem. 80, 11–16. ()

    Not in our library10.1016/s0162-0134(00)00033-7

  189. 189.

    Goldwaser I. Gefel D. Gershonov E. Fridkin M. Shechter Y. 2000 Insulin-like effects of vanadium: basic and clinical implications. J. Inorg. Biochem. 80, 21–25. ()

    Not in our library10.1016/s0162-0134(00)00035-0

  190. 190.

    Scior T. Guevara-García J. A. Melendez F. J. Abdallah H. Do Q. Bernard P. 2010 Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B. Drug Des. Dev. Ther. 4, 231–242.

    Not in our library

  191. 191.

    Li J. Guo S. J. Su H. Han L. J. Shi D. Y. 2008 Total synthesis of bis-(2,3-dibromo-4,5-dihydroxyphenyl)-methane as potent PTP1B inhibitor. Chin. Chem. Lett. 19, 1290–1292. ()

    Not in our library10.1016/j.cclet.2008.07.002

  192. 192.

    Li M. Ding W. Baruah B. Crans D. C. Wang R. 2008 Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato) oxovanadium (IV). J. Inorg. Biochem. 102, 1846–1853. ()

    Not in our library10.1016/j.jinorgbio.2008.06.007

  193. 193.

    Seale A. P. de Jesus L. A. Kim S.-Y. Choi Y.-H. Lim H. B. Hwang C.-S. Kim Y.-S. 2005 Development of an automated protein-tyrosine phosphatase 1B inhibition assay and the screening of putative insulin-enhancing vanadium(IV) and zinc(II) complexes. Biotechnol. Lett. 27, 221–225. ()

    Not in our library10.1007/s10529-004-7855-8

  194. 194.

    Scior T. Mack H.-G. Guevara-Garcia J. A. Koch W. 2008 Antidiabetic bis-maltolato-oxovanadium (IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B. Drug Des. Dev. Ther. 2, 221–231. ISSN: 1177–8881. ()

    Not in our library10.2147/dddt.s3732

  195. 195.

    Wang J. Yuen V. G. McNeill J. H. 2001 Effect of vanadium on insulin sensitivity and appetite. Metabolism 50, 667–673. ()

    Not in our library10.1053/meta.2001.23294

  196. 196.

    Shukla R. Bhonde R. R. 2008 Adipogenic action of vanadium: a new dimension in treating diabetes. Biometals 21, 205–210. ()

    Not in our library10.1007/s10534-007-9109-4

  197. 197.

    Hafez Y. Kratzer F. H. 1976 The effect of dietary vanadium on fatty acid and cholesterol synthesis and turnover in the chick. J. Nutr. 106, 249–257.

    Not in our library10.1093/jn/106.2.249

  198. 198.

    Upreti R. K. 1995 Membrane–vanadium interaction: a toxicokinetic evaluation. Mol. Cell Biochem. 153, 167–171. ()

    Not in our library10.1007/bf01075934

  199. 199.

    Barrio D. A. Cattáneo E. R. Apezteguía M. C. Etcheverry S. B. 2006 Vanadyl(IV) complexes with saccharides. Bioactivity in osteoblast-like cells in culture. Can. J. Physiol. Pharmacol. 84, 765–775. ()

    Not in our library10.1139/y06-021

  200. 200.

    Barrio D. A. Etcheverry S. B. 2006 Vanadium and bone development: putative signalling pathways. Can. J. Physiol. Pharmacol. 84, 677–686. ()

    Not in our library10.1139/y06-022

  201. 201.

    Cortizo A. M. Molinuevo M. S. Barrio D. A. Bruzzone L. 2006 Osteogenic activity of vanadyl(IV)-ascorbate complex: evaluation of its mechanism of action. Int. J. Biochem. Cell Biol. 38, 1171–1180. ()

    Not in our library10.1016/j.biocel.2005.12.007

  202. 202.

    Barrio D. A. Braziunas M. D. Etcheverry S. B. Cortizo A. M. 1997 Maltol complexes of vanadium(IV) and (V) regulate in vitro alkaline phosphatase activity and osteoblast-like cell growth. J. Trace Elem. Med. Biol. 11, 110–115. ()

    Not in our library10.1016/s0946-672x(97)80035-1

  203. 203.

    Barrio D. A. Williams P. A. Cortizo A. M. Etcheverry S. B. 2003 Synthesis of a new vanadyl(IV) complex with trehalose (TreVO): insulin-mimetic activities in osteoblast-like cells in culture. J. Biol. Metallic Chem. 8, 459–468.

    Not in our library10.1007/s00775-002-0438-z

  204. 204.

    Etcheverry S. B. Barrio D. A. Cortizo A. M. Williams P. A. 2002 Three new vanadyl(IV) complexes with non-steroidal anti-inflammatory drugs (Ibuprofen, Naproxen and Tolmetin). Bioactivity on osteoblast-like cells in culture. J. Metallic Biochem. 88, 94–100.

    Not in our library10.1016/s0162-0134(01)00368-3

  205. 205.

    Etcheverry S. B. Williams P. A. Salice V. C. Barrio D. A. Ferrer E. G. Cortizo A. M. 2002 Biochemical properties and mechanism of action of a vanadyl(IV)–aspirin complex on bone cell lines in culture. Biometals 15, 37–49. ()

    Not in our library10.1023/a:1013183910203

  206. 206.

    Yamaguchi M. Oishi H. Suketa Y. 1988 Zinc stimulation of bone protein synthesis in tissue culture: activation of aminoacyl-tRNA synthetase. Biochem. Pharmacol. 37, 4075–4080. ()

    Not in our library10.1016/0006-2952(88)90098-6

  207. 207.

    Ovesen J. Moller-Madsen B. Thomsen J. S. Danscher G. Mosekilde L. 2001 The positive effects of zinc on skeletal strength in growing rats. Bone 29, 565–570. ()

    Not in our library10.1016/s8756-3282(01)00616-0

  208. 208.

    Haimi S. 2009 Characterization of zinc-releasing three-dimensional bioactive glass scaffolds and their effect on human adipose stem cell proliferation and osteogenic differentiation. Acta Biomater. 5, 3122–3131. ()

    Not in our library10.1016/j.actbio.2009.04.006

  209. 209.

    Chen D. Waite L. Pierce W. 1999 In vitro effects of zinc on markers of bone formation. Biol. Trace Elem. Res. 68, 225–234.

    Not in our library10.1007/bf02783905)

  210. 210.

    Yin Y. Cui Q. Li Y. Irwin N. Fischer D. Harvey A. R. Benowitz L. I. 2003 Macrophage-derived factors stimulate optic nerve regeneration. J. Neurosci. 23, 2284–2293.

    Not in our library10.1523/jneurosci.23-06-02284.2003

  211. 211.

    Diamond I. Hurley L. S. 1970 Histopathology of zinc-deficient fetal rats. J. Nutr. 100, 325–329.

    Not in our library10.1093/jn/100.3.325

  212. 212.

    Hall S. L. Dimai H. P. Farley J. R. 1999 Effects of zinc on human skeletal alkaline phosphatase activity in vitro. Calcif. Tissue Int. 64, 163–172. ()

    Not in our library10.1007/s002239900597

  213. 213.

    Kawamura H. Ito A. Muramatsu T. Miyakawa S. Ochiai N. Tateishi T. 2003 Long-term implantation of zinc-releasing calcium phosphate ceramics in rabbit femora. J. Biomed. Mater. Res. A 65, 468–474. ()

    Not in our library10.1002/jbm.a.10524

  214. 214.

    Ikeuchi M. Ito A. Dohi Y. Ohgushi H. Shimaoka H. Yonemasu K. Tateishi T. 2003 Osteogenic differentiation of cultured rat and human bone marrow cells on the surface of zinc-releasing calcium phosphate ceramics. J. Biomed. Mater. Res. A 67, 1115–1122. ()

    Not in our library10.1002/jbm.a.10041

  215. 215.

    Popp J. R. Love B. J. Goldstein A. S. 2007 Effect of soluble zinc on differentiation of osteoprogenitor cells. J. Biomed. Mater. Res. A 81, 766–769 ().

    Not in our library10.1002/jbm.a.31214

  216. 216.

    Yamaguchi M. Oishi H. Suketa Y. 1987 Stimulatory effect of zinc on bone formation in tissue culture. Biochem. Pharmacol. 36, 4007–4012. ()

    Not in our library10.1016/0006-2952(87)90471-0

  217. 217.

    Kwun I.-S. Cho Y.-E. Lomeda R.-A. R. Shin H.-I. Choi J.-Y. Kang Y.-H. Beattie J. H. 2010 Zinc deficiency suppresses matrix mineralization and retards osteogenesis transiently with catchup possibly through Runx 2 modulation. Bone 46, 732–741. ()

    Not in our library10.1016/j.bone.2009.11.003

  218. 218.

    Aedo F. Delgado R. Wolff D. Vergara C. 2007 Copper and zinc as modulators of neuronal excitability in a physiologically significant concentration range. Neurochem. Int. 50, 591–600. ()

    Not in our library10.1016/j.neuint.2006.12.001

  219. 219.

    Lang C. Murgia C. Leong M. Tan L.-W. Perozzi G. Knight D. Ruffin R. Zalewski P. 2007 Anti-inflammatory effects of zinc and alterations in zinc transporter mRNA in mouse models of allergic inflammation. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L577–L584. ()

    Not in our library10.1152/ajplung.00280.2006

  220. 220.

    Cho Y. H. Lee S. J. Lee J. Y. Kim S. W. Lee C. B. Lee W. Y. Yoon M. S. 2002 Antibacterial effect of intraprostatic zinc injection in a rat model of chronic bacterial prostatitis. Int. J. Antimicrob. Agents 19, 576–582. ()

    Not in our library10.1016/s0924-8579(02)00115-2

  221. 221.

    Lansdown A. B. Mirastschijski U. Stubbs N. Scanlon E. Agren M. S. 2007 Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound Repair Regen. 15, 2–16. ()

    Not in our library10.1111/j.1524-475x.2006.00179.x

  222. 222.

    Kothapalli C. R. Ramamurthi A. 2009 Copper nanoparticle cues for biomimetic cellular assembly of crosslinked elastin fibers. Acta Biomater. 5, 541–553. ()

    Not in our library10.1016/j.actbio.2008.09.004

  223. 223.

    Chen X. Liao X. Huang Z. You P. Chen C. Kang Y. Guangfu Y. 2010 Synthesis and characterization of novel multiphase bioactive glass–ceramics in the CaO–MgO–SiO2 system. J. Biomed. Mater. Res. B 93, 194–202.

    Not in our library10.1002/jbm.b.31574

  224. 224.

    Saboori A. Rabiee M. Moztarzadeh F. Sheikhi M. Tahriri M. Karimi M. 2009 Synthesis, characterization and in vitro bioactivity of sol–gel-derived SiO2–CaO–P2O5–MgO bioglass. Mater. Sci. Eng. C 29, 335–340. ()

    Not in our library10.1016/j.msec.2008.07.004

  225. 225.

    Mayer I. Jacobsohn O. Niazov T. Werckmann J. Iliescu M. Richard-Plouet M. Burghaus O. Reinen D. 2003 Manganese in precipitated hydroxyapatites. Eur. J. Inorg. Chem. 7, 1445–1451. ()

    Not in our library10.1002/ejic.200390188

  226. 226.

    Li Y. Teck Nam C. H. Ping Ooi C. H. 2009 Iron(III) and manganese(II) substituted hydroxyapatite nanoparticles: characterization and cytotoxicity analysis. J. Phys. Conf. Ser. 187, 012024 ()

    Not in our library10.1088/1742-6596/187/1/012024

  227. 227.

    Bellantone M. Coleman N. J. Hench L. L. 2000 Bacteriostatic action of a novel four-component bioactive glass. J. Biomed. Mater. Res. 51, 484–491. ()

    Not in our library10.1002/1097-4636(20000905)51:3<484::aid-jbm24>3.0.co;2-4

  228. 228.

    Bellantone M. Williams H. D. Hench L. L. 2002 Broad-spectrum bactericidal activity of Ag2O-doped bioactive glass. Antimicrob. Agents Chemother. 46, 1940–1945. ()

    Not in our library10.1128/aac.46.6.1940-1945.2002

  229. 229.

    Pratten J. Nazhat S. N. Blaker J. J. Boccaccini A. R. 2004 In vitro attachment of Staphylococcus epidermidis to surgical sutures with and without Ag-containing bioactive glass coating. J. Biomater. Appl. 19, 47–57. ()

    Not in our library10.1177/0885328204043200

  230. 230.

    Newby P. J. El-Gendy R. Kirkham J. Yang X. B. Thompson I. D. Boccaccini A. R. 2011 Ag-doped 45S5 bioglass-based bone scaffolds by molten salt ion exchange: processing and characterisation. J. Mater. Sci. Mater. Med. 22, 557–569. ()

    Not in our library10.1007/s10856-011-4240-8

  231. 231.

    Landi E. Tampieri A. Celotti G. Sprio S. Sandra M. Logroscino G. 2007 Sr-substituted hydroxyapatites for osteoporotic bone replacement. Acta Biomater. 3, 961–969. ()

    Not in our library10.1016/j.actbio.2007.05.006

  232. 232.

    Hesaraki S. Alizadeh M. Nazarian H. Sharifi D. 2010 Physico-chemical and in vitro biological evaluation of strontium/calcium silicophosphate glass. J. Mater. Sci. Mater. Med. 21, 695–705. ()

    Not in our library10.1007/s10856-009-3920-0

  233. 233.

    Gentleman E. Fredholm Y. C. Jell G. Lotfibakhshaiesh N. O'Donnell M. D. Hill R. G. Stevens M. M. 2010 The effects of strontium-substituted bioactive glasses on osteoblasts and osteoclasts in vitro. Biomaterials 31, 3949–3956. ()

    Not in our library10.1016/j.biomaterials.2010.01.121

  234. 234.

    Zhang M. L. Zhai W. Y. Lin K. L. Pan H. B. Lu W. Chang J. 2010 Synthesis, in vitro hydroxyapatite forming ability, and cytocompatibility of strontium silicate powders. J. Biomed. Mater. Res. B Appl. Biomater. 93, 252–257.

    Not in our library10.1002/jbm.b.31582

  235. 235.

    Wu C. H Fan W. Gelinsky M. Xiao Y. Simon P. Schulze R. Doert T. Luo Y. Cuniberti G. 2011 Bioactive SrO–SiO2 glass with well-ordered mesopores: characterization, physiochemistry and biological properties. Acta Biomater. 7, 1797–1806. ()

    Not in our library10.1016/j.actbio.2010.12.018

  236. 236.

    Isaac J. Nohra J. Lao J. Jallot E. Nedelec J. M. Berdal A. Sautier J. M. 2011 Effects of strontium-doped bioactive glass on the differentiation of cultured osteogenic cells. Eur. Cells Mater. 21, 130–143.

    Not in our library10.22203/ecm.v021a11

  237. 237.

    Webster T. J. Ergun C. Doremus R. H. Bizios R. 2002 Hydroxyapatite with substituted magnesium, zinc, cadmium, and yttrium. II. Mechanisms of osteoblast adhesion. J. Biomed. Mater. Res. A 59, 312–317. ()

    Not in our library10.1002/jbm.1247

  238. 238.

    Balamurugan A. Balossier G. Kannan S. Michel J. Rebelo A. H. S. Ferreira J. M. F. 2007 Development and in vitro characterization of sol–gel derived CaO–P2O5–SiO2–ZnO bioglass. Acta Biomater. 3, 255–262. ()

    Not in our library10.1016/j.actbio.2006.09.005

  239. 239.

    Salih V. Patel A. Knowles J. C. 2007 Zinc-containing phosphate-based glasses for tissue engineering. Biomed. Mater. 2, 11–20. ()

    Not in our library10.1088/1748-6041/2/1/003

  240. 240.

    Boyd D. Li H. Tanner D. A. Towler M. R. Wall J. G. 2006 The antibacterial effects of zinc ion migration from zinc-based glass polyalkenoate cements. J. Mater. Sci. Mater. Med. 17, 489–494. ()

    Not in our library10.1007/s10856-006-8930-6

  241. 241.

    Aina V. Malavasi G. Fiorio Pla A. Munaron L. Morterra C. 2008 Zinc-containing bioactive glasses: surface reactivity and behaviour towards endothelial cells. Acta Biomater. 5, 1211–1222. ()

    Not in our library10.1016/j.actbio.2008.10.020

  242. 242.

    Murphy S. Boyd D. Moane S. Bennett M. 2009 The effect of composition on ion release from Ca–Sr–Na–Zn–Si glass bone grafts. J. Mater. Sci. Mater. Med. 20, 2207–2214. ()

    Not in our library10.1007/s10856-009-3789-y

  243. 243.

    Zreiqat H. 2010 The incorporation of strontium and zinc into a calcium–silicon ceramic for bone tissue engineering. Biomaterials 31, 3175–3184. ()

    Not in our library10.1016/j.biomaterials.2010.01.024

  244. 244.

    Matsumoto N. Sato K. Yoshida K. Hashimoto K. Toda Y. 2009 Preparation and characterization of β-tricalcium phosphate co-doped with monovalent and divalent antibacterial metal ions. Acta Biomater. 5, 3157–3164. ()

    Not in our library10.1016/j.actbio.2009.04.010

  245. 245.

    Boyd D. Carroll G. Towler M. R. Freeman C. Farthing P. Brook I. M. 2009 Preliminary investigation of novel bone graft substitutes based on strontium–calcium–zinc–silicate glasses. J. Mater. Sci. Mater. Med. 20, 413–420. ()

    Not in our library10.1007/s10856-008-3569-0

  246. 246.

    Yazar M. Sarban S. Kocyigit A. Isikan U. E. 2005 Synovial fluid and plasma selenium, copper, zinc, and iron concentrations in patients with rheumatoid arthritis and osteoarthritis. Biol. Trace Elem. Res. 106, 123–132. ()

    Not in our library10.1385/bter:106:2:123

  247. 247.

    Ladon D. Doherty A. Newson R. Turner J. Bhamra M. Case C. P. 2004 Changes in metal levels and chromosome aberrations in the peripheral blood of patients after metal-on-metal hip arthroplasty. J. Arthroplasty 19(Suppl. 83), 78–83. ()

    Not in our library10.1016/j.arth.2004.09.010

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.